Montelukast

18 interactions 188 cited references
Also sold as: Singulair Singulair®
About Montelukast

Montelukast is a leukotriene receptor antagonist used to prevent asthma symptoms and treat allergic rhinitis. Read the full Montelukast drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Teriflunomide Omaveloxolone Phenobarbital Pixantrone Olanzapine Vorasidenib
14 Major 3 Moderate 1 Minor
All (18) Major (14) Moderate (3) Minor (1)

Major

Montelukast Abiraterone Abirtega Increased CYP2C8 substrate exposure and an increased risk of CYP2C8 substrate-related adverse effects Details Montelukast Leflunomide Arava Increased exposure of CYP2C8 substrate Details Montelukast Abiraterone Acetate Abirtega Increased CYP2C8 substrate exposure and an increased risk of CYP2C8 substrate-related adverse effects Details Montelukast Abiraterone Acetate, Micronized Abirtega Increased CYP2C8 substrate exposure and an increased risk of CYP2C8 substrate-related adverse effects Details Montelukast Cannabidiol Epidiolex Increased CYP2C8 substrate exposure and an increased risk of CYP2C8 substrate-related adverse reactions Details Montelukast Carbamazepine Carbatrol Reduced CYP2C8 substrate exposure and reduced efficacy of CYP2C8 substrate Details Montelukast Dasabuvir Increased dasabuvir concentration Details Montelukast Olanzapine Reduced OLANZapine exposure and reduced efficacy of OLANZapine Details Montelukast Omaveloxolone Skyclarys Reduced CYP2C8 substrate exposure and reduced efficacy of CYP2C8 substrate Details Montelukast Phenobarbital Fidoquel Reduced montelukast exposure and reduced efficacy of montelukast Details Montelukast Pixantrone Increased exposure of CYP2C8 substrates Details Montelukast Teriflunomide Aubagio Increased exposure of CYP2C8 substrate Details Montelukast Vorasidenib Voranigo Reduced vorasidenib exposure and reduced anti-tumor activity of vorasidenib Details Montelukast Warfarin Coumadin Reduced warfarin exposure and reduced INR Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.